Department of Neurology, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense de Madrid, Hospital Clinico San Carlos, Madrid, Spain
Auto-generated profile, based on publicly available information
Lucía Fernández-Romero
Department of Neurology, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense de Madrid, Hospital Clinico San Carlos, Madrid, Spain
Background: Non-invasive brain stimulation has shown positive results in maximizing the effects of language therapy in primary progressive aphasia (PPA). Due to the different patterns of brain damage in each aphasia variant, we hypothesized that patients with non-fluent and semantic variants would show a differential response to transcranial magnetic stimulation (TMS). Objective: We aimed to compare the clinical responses after a single session of repetitive TMS in the left inferior frontal gyrus (IFG) and the left dorsolateral prefrontal cortex (DLPC). Methodology: Twenty patients with PPA (14 with non-fluent and 6 with semantic variants) were assessed before and after repetitive TMS over the IFG, DLPC, and vertex with several language tasks, connected speech, and a subjective impression of change scale. Results: IFG stimulation was associated with an improvement in words per minute and the subjective assessment in the non-fluent variant, but no effects were found in the semantic variant. DLPC stimulation was associated with an improvement in words per minute, repetition, and naming latency in the non-fluent variant, and in naming and subjective impression of change in the semantic variant. Conclusions: Our study showed a differential effect of one session of brain stimulation over the IFG and DLPC in patients with non-fluent and semantic PPA variants. These findings suggest that the selection of the target of stimulation may be relevant for the success of brain stimulation and favor the use of DLPC over the IFG.
22 January 2026 in Parkinsonism & Related Disorders
Introduction Primary progressive aphasia (PPA) is a neurodegenerative syndrome associated with Alzheimer’s disease and frontotemporal degeneration. Non-invasive brain stimulation (NIBS) is a promising treatment, especially associated with language therapy, but comparative efficacy and long-term effects between the different techniques (transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)) remain unknown. The present study aims to investigate the effects of non-invasive brain stimulation, alone or associated (tDCS/TMS/tDCS plus TMS) combined with language therapy delivered during a period of 6 months, in the progression of language impairment in PPA, compared with sham stimulation combined with language therapy. Methods and analysis The study is a randomised, double-blinded, parallel, sham-controlled clinical trial. Patients with PPA in early stages (global Clinical Dementia Rating equal to or less than 1) are eligible. They are to be randomised to one of the four treatment arms of the study (active tDCS-active TMS, active tDCS-sham TMS, sham tDCS-active TMS, sham tDCS-sham TMS). All patients will receive language therapy immediately after each session of NIBS, for 6 months. The primary outcome is the Mini-Linguistic State Examination. The secondary outcomes are naming of trained items, Addenbrooke’s Cognitive Examination, Interview for Deterioration in Daily Living Activities, Clinical Dementia Rating including behaviour and language domains, Neuropsychiatric Inventory and regional brain metabolism. Exploratory substudies will be conducted including blood biomarkers, quantitative electroencephalography and spontaneous speech assessment. Ethics and dissemination The study is registered (ClinicalTrials.gov: NCT07158216) and approved by the Ethics Committee of the Hospital Clinico San Carlos (code 25/309-IC_P_CE). Patients will be enrolled after signing an informed consent form. Study outcomes will be disseminated through presentations at scientific conferences, publications in peer-reviewed journals and other academic forums. Trial registration number NCT07158216.